Journal article
Methotrexate in psoriasis and psoriatic arthritis
- Abstract:
- Methotrexate (MTX) is the most commonly prescribed first-line therapy in psoriatic arthritis (PsA) internationally and is also commonly used in the treatment of psoriasis. However, data supporting its use in PsA are limited and significant toxicities can occur. This article summarises a debate at the 2019 GRAPPA annual meeting that focused on the use of MTX in psoriasis and PsA. Four clinicians and one patient research partner presented clinical study data and the patient experience summarising the efficacy, tolerability and toxicity of MTX for both skin and musculoskeletal manifestations. A live survey of attending GRAPPA members collected data on current and planned future use of MTX across the world.
- Publication status:
- Accepted
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 274.3KB, Terms of use)
-
- Publisher copy:
- 10.3899/jrheum.200124
Authors
- Publisher:
- Journal of Rheumatology
- Journal:
- Journal of Rheumatology More from this journal
- Volume:
- 96
- Issue:
- June 2020
- Pages:
- 31-35
- Publication date:
- 2020-06-01
- Acceptance date:
- 2020-01-31
- DOI:
- EISSN:
-
1499-2752
- ISSN:
-
0315-162X
- Language:
-
English
- Keywords:
- Pubs id:
-
1086571
- Local pid:
-
pubs:1086571
- Deposit date:
-
2020-02-10
- ARK identifier:
Terms of use
- Copyright date:
- 2020
- Rights statement:
- © 2020
- Notes:
- This is the accepted manuscript version of the article. The final version is available from Journal of Rheumatology at: https://doi.org/10.3899/jrheum.200124
If you are the owner of this record, you can report an update to it here: Report update to this record